Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease
- 1 July 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 17 (7) , 1092-1103
Abstract
Diabetic kidney disease is the most frequent cause of kidney failure, accounting for half of all cases worldwide. Moreover, deaths from diabetic kidney disease increased 106% between 1990 and 2013, with most attributed to cardiovascular disease. Recommended screening and monitoring for diabetic kidney disease are conducted in less than half of patients with diabetes. Standard-of-care treatment with an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker is correspondingly low. Sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and a nonsteroidal mineralocorticoid antagonist are highly effective therapies to reduce kidney and cardiovascular risks in diabetic kidney disease. However, <20% of eligible patients are receiving these agents. Critical barriers are high out-of-pocket drug costs and low reimbursement rates. Data demonstrating clinical and cost-effectiveness of diabetic kidney disease care are needed to garner payer and health care system support. The pharmaceutical industry should collaborate on value-based care by increasing access through affordable drug prices. Additionally, multidisciplinary models and communication technologies tailored to individual health care systems are needed to support optimal diabetic kidney disease care. Community outreach efforts are also central to make care accessible and equitable. Finally, it is imperative that patient preferences and priorities shape implementation strategies. Access to care and implementation of breakthrough therapies for diabetic kidney disease can save millions of lives by preventing kidney failure, cardiovascular events, and premature death. Coalitions composed of patients, families, community groups, health care professionals, health care systems, federal agencies, and payers are essential to develop collaborative models that successfully address this major public health challenge.Keywords
This publication has 46 references indexed in Scilit:
- The Global Epidemiology of Diabetes and Kidney DiseaseAdvances in Chronic Kidney Disease, 2018
- Diabetic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2017
- Vital Signs: Decrease in Incidence of Diabetes-Related End-Stage Renal Disease among American Indians/Alaska Natives — United States, 1996–2013MMWR. Morbidity and Mortality Weekly Report, 2017
- Effects of Community-Based Health Worker Interventions to Improve Chronic Disease Management and Care Among Vulnerable Populations: A Systematic ReviewAmerican Journal of Public Health, 2016
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013The Lancet, 2015
- Changes in Diabetes-Related Complications in the United States, 1990–2010New England Journal of Medicine, 2014
- Reported Racial Discrimination, Trust in Physicians, and Medication Adherence Among Inner-City African Americans With HypertensionAmerican Journal of Public Health, 2013
- Relative Incidence of ESRD Versus Cardiovascular Mortality in Proteinuric Type 2 Diabetes and Nephropathy: Results From the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) DatabaseAmerican Journal of Kidney Diseases, 2012
- Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant RecipientsAmerican Journal of Transplantation, 2009